Recent trials have shown a benefit with maintenance therapy after 4 to 6 cycles of chemotherapy. These trials have shown improvement in progression-free survival using agents approved as second-line therapy in non-small cell lung cancer. Trials using erlotinib and pemetrexed showed improvement in overall survival. Consideration of trial design is critical for the interpretation of these results. Data on quality of life and cost have not been presented, but will ultimately be important in evaluating the usefulness of these approaches.
Correspondence: Renato G. Martins, MD, MPH, Thoracic/Head and Neck Medical Oncology, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/University of Washington, 825 Eastlake Avenue East, Seattle, WA 98109. E-mail: email@example.com
Disclosure: Keith D. Eaton, MD, PhD, has disclosed that he has participated in funded research on technology, process, or product development for OSI, Genentech, NovaRx, Merck, Novartis, Pfizer, and Boehringer Ingelheim.
Disclosure: Renato G. Martins, MD, MPH, has disclosed that he has participated in funded or unfunded research on a technology, process, or product development for Lilly (PI), OSI (Sub-I), and Genentech (Sub-I), and that he has received compensation as a speaker from Lilly and Genentech.